Acadia Pharmaceuticals
ACAD
ACAD
275 hedge funds and large institutions have $5.04B invested in Acadia Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 105 increasing their positions, 70 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
11% more funds holding
Funds holding: 247 → 275 (+28)
2.69% more ownership
Funds ownership: 95.3% → 97.99% (+2.7%)
10% less call options, than puts
Call options by funds: $29.2M | Put options by funds: $32.5M
Holders
275
Holding in Top 10
9
Calls
$29.2M
Puts
$32.5M
Top Buyers
| 1 | +$43.3M | |
| 2 | +$39.2M | |
| 3 | +$30M | |
| 4 |
Morgan Stanley
New York
|
+$27.2M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$25.3M |
Top Sellers
| 1 | -$41.3M | |
| 2 | -$32.4M | |
| 3 | -$20.3M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$19.6M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$18.3M |